New study to see if tezepelumab tames severe asthma in daily life

NCT ID NCT06566885

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 125 people aged 12 and older with severe asthma who are starting tezepelumab in Russia. Over 52 weeks, researchers will track how well their symptoms are controlled using a standard questionnaire. The goal is to see how the drug works outside of clinical trials, in real-world conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tezepelumab
What this could lead to: If successful, this study could show that tezepelumab helps people with severe asthma gain better symptom control in real-world settings.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by other factors. It is also small (125 people) and limited to Russia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE ASTHMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma chronic asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SEVERE ASTHMA

Contacts and locations

Locations

Research Site

Kaliningrad, Russia
Research Site

Kemerovo, Russia
Research Site

Krasnodar, Russia
Research Site

Moscow, Russia
Research Site

Nal'chik, Russia
Research Site

Nizhny Novgorod, Russia
Research Site

Novosibirsk, Russia
Research Site

Orenburg, Russia
Research Site

Petrozavodsk, Russia
Research Site

Saint Petersburg, Russia
Research Site

Shelehov, Russia
Research Site

Stavropol, Russia
Research Site

Tomsk, Russia
Research Site

Ulan-Ude, Russia
Research Site

Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.